Anti-cancer drug KP1019 induces Hog1 phosphorylation and protein ubiquitylation in Saccharomyces cerevisiae

European Journal of Pharmacology

Volumn 736, Issue , 2014, Pages 77-85

  Singh, Vikash ^a   Azad, Gajendra Kumar ^a   Reddy M , Amarendar ^a   Baranwal, Shivani ^a   Tomar, Raghuvir S ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

Author keywords

Anti cancer drug; GPD1 up regulation; Hog1 phosphorylation; KP1019; Mitogen activated protein kinases; Protein ubiquitination

Indexed keywords

ANTINEOPLASTIC AGENT; HIGH OSMOLARITY GLYCEROL 1 PROTEIN; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; INDAZOLIUM [TETRACHLORIDOBIS(1H INDAZOLE)RUTHENATE]; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; GLYCEROL 3 PHOSPHATE DEHYDROGENASE (NAD); GPD1 PROTEIN, S CEREVISIAE; HOG1 PROTEIN, S CEREVISIAE; INDAZOLE DERIVATIVE; INDAZOLIUM TRANS-(TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)); ORGANOMETALLIC COMPOUND; SACCHAROMYCES CEREVISIAE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; GENE; GENE EXPRESSION; GLYCEROL 3 PHOSPHATE DEHYDROGENASE 1 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; SACCHAROMYCES CEREVISIAE; UBIQUITINATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; GLYCEROL-3-PHOSPHATE DEHYDROGENASE (NAD+); INDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASES; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLATION; RNA, MESSENGER; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; UBIQUITINATION; UP-REGULATION;

EID: 84900355024     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.04.032     Document Type: Article

References (40)

1. J.B. Aitken, S. Antony, C.M. Weekley, B. Lai, L. Spiccia, and H.H. Harris Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells Metall.: Integr. Biomet. Sci. 4 2012 1051 1056 (1007)
2. J. Albertyn, S. Hohmann, J.M. Thevelein, and B.A. Prior Gpd1, which encodes glycerol-3-phosphate dehydrogenase, is essential for growth under osmotic-stress in Saccharomyces cerevisiae, and its expression is regulated by the high-osmolarity glycerol response pathway Mol. Cell. Biol. 14 1994 4135 4144
3. J. Albertyn, S. Hohmann, J.M. Thevelein, and B.A. Prior GPD1, which encodes glycerol-3-phosphate dehydrogenase, is essential for growth under osmotic stress in Saccharomyces cerevisiae, and its expression is regulated by the high-osmolarity glycerol response pathway Mol. Cell. Biol. 14 1994 4135 4144
4. G.K. Azad, S.J. Balkrishna, N. Sathish, S. Kumar, and R.S. Tomar Multifunctional Ebselen drug functions through the activation of DNA damage response and alterations in nuclear proteins Biochem. Pharmacol. 83 2012 296 303
5. G.K. Azad, V. Singh, U. Golla, and R.S. Tomar Depletion of cellular iron by curcumin leads to alteration in histone acetylation and degradation of Sml1p in Saccharomyces cerevisiae PloS One 8 2013 e59003
6. G.K. Azad, V. Singh, P. Mandal, P. Singh, U. Golla, S. Baranwal, S. Chauhan, and R.S. Tomar Ebselen induces reactive oxygen species (ROS)-mediated cytotoxicity in Saccharomyces cerevisiae with inhibition of glutamate dehydrogenase being a target FEBS Open Bio 4 2014 77 89
7. G.K. Azad, V. Singh, and R.S. Tomar Assessment of the biological pathways targeted by isocyanate using N-succinimidyl N-methylcarbamate in budding yeast Saccharomyces cerevisiae PloS One 9 2014 e92993
8. S.J. Balkrishna, S. Kumar, G.K. Azad, B.S. Bhakuni, P. Panini, N. Ahalawat, R.S. Tomar, and M.R. Detty An ebselen like catalyst with enhanced GPx activity via a selenol intermediate Org. Biomol. Chem. 12 2014 1215 1219
9. M.R. Berger, F.T. Garzon, B.K. Keppler, and D. Schmahl Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats Anticancer Res. 9 1989 761 765
10. F. Bersani, R. Taulli, P. Accornero, A. Morotti, S. Miretti, T. Crepaldi, and C. Ponzetto Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma Eur. J. Cancer 44 2008 876 884
11. V. Brabec DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair Prog. Nucleic Acid Res. 71 2002 1 68
12. J.L. Brewster, T. de Valoir, N.D. Dwyer, E. Winter, and M.C. Gustin An osmosensing signal transduction pathway in yeast Science 259 1993 1760 1763
13. K. Deacon, P. Mistry, J. Chernoff, J.L. Blank, and R. Patel p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest Mol. Biol. Cell 14 2003 2071 2087
14. P. Ferrigno, F. Posas, D. Koepp, H. Saito, and P.A. Silver Regulated nucleo/cytoplasmic exchange of HOG1 MAPK requires the importin beta homologs NMD5 and XPO1 EMBO J. 17 1998 5606 5614
15. U. Golla, V. Singh, G.K. Azad, P. Singh, N. Verma, P. Mandal, S. Chauhan, and R.S. Tomar Sen1p contributes to genomic integrity by regulating expression of ribonucleotide reductase 1 (RNR1) in Saccharomyces cerevisiae PloS One 8 2013 e64798
16. J.U. Gutterman, H.T. Lai, P. Yang, V. Haridas, A. Gaikwad, and S. Marcus Effects of the tumor inhibitory triterpenoid avicin G on cell integrity, cytokinesis, and protein ubiquitination in fission yeast Proc. Natl. Acad. Sci. USA 102 2005 12771 12776
17. C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P.J. Dyson, and B.K. Keppler KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients Chem. Biodivers. 5 2008 2140 2155
18. C.G. Hartinger, S. Zorbas-Seifried, M.A. Jakupec, B. Kynast, H. Zorbas, and B.K. Keppler From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H- indazole)ruthenate(III)] (KP1019 or FFC14A) J. Inorg. Biochem. 100 2006 891 904
19. P. Heffeter, K. Bock, B. Atil, M.A.R. Hoda, W. Korner, C. Bartel, U. Jungwirth, B.K. Keppler, M. Micksche, W. Berger, and G. Koellensperger Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 J. Biol. Inorg. Chem. 15 2010 737 748
20. P. Heffeter, M. Pongratz, E. Steiner, P. Chiba, M.A. Jakupec, L. Elbling, B. Marian, W. Korner, F. Sevelda, M. Micksche, B.K. Keppler, and W. Berger Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (FFC14A) J. Pharmacol. Exp. Ther. 312 2005 281 289
21. J. Hernandez Losa, C. Parada Cobo, J. Guinea Viniegra, V.J. Sanchez-Arevalo Lobo, S. Ramon y Cajal, and R. Sanchez-Prieto Role of the p38 MAPK pathway in cisplatin-based therapy Oncogene 22 2003 3998 4006
22. A. Hershko, and A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425 479
23. W.F. Holmes, D.R. Soprano, and K.J. Soprano Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line J. Biol. Chem. 277 2002 45408 45419
24. S. Kapitza, M.A. Jakupec, M. Uhl, B.K. Keppler, and B. Marian The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells Cancer Lett. 226 2005 115 121
25. F. Kratz, M. Hartmann, B. Keppler, and L. Messori The binding properties of two antitumor ruthenium(III) complexes to apotransferrin J. Biol. Chem. 269 1994 2581 2588
26. C.L. Lawrence, C.H. Botting, R. Antrobus, and P.J. Coote Evidence of a new role for the high-osmolarity glycerol mitogen-activated protein kinase pathway in yeast: regulating adaptation to citric acid stress Mol. Cell. Biol. 24 2004 3307 3323
27. F. Lentz, A. Drescher, A. Lindauer, M. Henke, R.A. Hilger, C.G. Hartinger, M.E. Scheulen, C. Dittrich, B.K. Keppler, and U. Jaehde Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study Anticancer Drugs 20 2009 97 103
28. K.G. Lipponer, E. Vogel, and B.K. Keppler Synthesis, characterization and solution chemistry of trans-indazoliumtetrachlorobis(indazole)ruthenate(III), a new anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. Crystal structures of trans-1-methyl- indazoliumtetrachlorobis-(1-methylindazole)ruthenate(III) and its hydrolysis product trans-monoaquatrichlorobis-(1-methylindazole)-ruthenate(III) Met.-Based Drugs 3 1996 243 260
29. T. Maeda, S.M. Wurgler-Murphy, and H. Saito A two-component system that regulates an osmosensing MAP kinase cascade in yeast Nature 369 1994 242 245
30. G. Mandili, A. Khadjavi, V. Gallo, V.G. Minero, L. Bessone, F. Carta, G. Giribaldi, and F. Turrini Characterization of the protein ubiquitination response induced by Doxorubicin FEBS J. 279 2012 2182 2191
31. J.M. Marques, R.J. Rodrigues, A.C. de Magalhaes-Sant'Ana, and T. Goncalves Saccharomyces cerevisiae Hog1 protein phosphorylation upon exposure to bacterial endotoxin J. Biol. Chem. 281 2006 24687 24694
32. M. Pongratz, P. Schluga, M.A. Jakupec, V.B. Arion, C.G. Hartinger, G. Allmaier, and B.K. Keppler Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy J. Anal. At. Spectrom. 19 2004 46 51
33. F. Posas, and H. Saito Activation of the yeast SSK2 MAP kinase kinase kinase by the SSK1 two-component response regulator EMBO J. 17 1998 1385 1394
34. F. Posas, S.M. WurglerMurphy, T. Maeda, E.A. Witten, T.C. Thai, and H. Saito Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 "two-component" osmosensor Cell 86 1996 865 875
35. M. Proft, A. Pascual-Ahuir, E. de Nadal, J. Arino, R. Serrano, and F. Posas Regulation of the Sko1 transcriptional repressor by the Hog1 MAP kinase in response to osmotic stress EMBO J. 20 2001 1123 1133
36. G. Sava, and A. Bergamo Ruthenium-based compounds and tumour growth control (review) Int. J. Oncol. 17 2000 353 365
37. G. Sava, I. Capozzi, K. Clerici, G. Gagliardi, E. Alessio, and G. Mestroni Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex Clin. Exp. Metastasis 16 1998 371 379
38. V. Singh, G.K. Azad, P. Mandal, M. Amarendar Reddy, and R.S. Tomar Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae FEBS Lett. 588 2014 1044 1052
39. S.K. Stevens, A.P. Strehle, R.L. Miller, S.H. Gammons, K.J. Hoffman, J.T. McCarty, M.E. Miller, L.K. Stultz, and P.K. Hanson The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae Mol. Pharmacol. 83 2013 225 234
40. A. Winkler, C. Arkind, C.P. Mattison, A. Burkholder, K. Knoche, and I. Ota Heat stress activates the yeast high-osmolarity glycerol mitogen-activated protein kinase pathway, and protein tyrosine phosphatases are essential under heat stress Eukaryotic Cell 1 2002 163 173